Brief: Xspray Pharma Partners With Eversana
Feb 23 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST :
* XSPRAY PHARMA PARTNERS WITH EVERSANA FOR THE U.S. LAUNCH
AND
COMMERCIALIZATION OF ITS LEAD PRODUCT, DASYNOC (XS004) FOR THE
TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHATIC
LEUKEMIA (ALL)
Source text for Eikon: ID:nMFNvBXqk
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003